BiotechTube
Be Biopharma

Be Biopharma

Cambridge, United States· Est.
be.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $352M

Overview

Be Biopharma is a private, clinical-stage biotech based in Cambridge, MA, developing Engineered B Cell Medicines (BCMs). The company has advanced its lead candidate, BE-101 for hemophilia B, into a Phase 1/2 clinical trial (BeCoMe-9) and is building a broader pipeline, including BE-102 for hypophosphatasia. Backed by over $260 million from a syndicate of top-tier life science investors, Be Bio aims to leverage the natural biology of B cells to create a new modality for protein replacement and beyond.

Rare DiseasesHematologyMetabolic Disorders

Technology Platform

Proprietary platform for engineering autologous B cells to become durable, in vivo factories for therapeutic protein production (Engineered B Cell Medicines - BCMs).

Funding History

3
Total raised:$352M
Venture$92M
Series B$130M
Series A$130M

Opportunities

The platform could address multi-billion dollar markets in rare diseases (e.g., hemophilia) by offering a potentially durable, re-dosable, and controllable alternative to existing gene and protein therapies.
Its modular nature allows for expansion into large therapeutic areas like oncology and autoimmunity by engineering B cells to secrete antibodies, cytokines, or other complex biologics.

Risk Factors

The core technology is unproven in humans, with risks around long-term engraftment, immunogenicity, and precise control of protein production.
The company faces intense competition in its initial indications from established protein therapies and newer gene therapies, requiring a best-in-class clinical profile.

Competitive Landscape

In hemophilia, Be Bio competes with established factor replacement therapies, non-factor therapies (e.g., Hemlibra), and approved gene therapies (e.g., Hemgenix). More broadly, its BCM platform represents a novel modality competing with viral vector-based gene therapy, enzyme replacement therapy, and conventional biologic drug formats. Success hinges on demonstrating superior durability, safety, or controllability.

More companies in Cell & Gene Therapy →More companies in United States →